{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:27:12Z","timestamp":1787095632724,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Padjadjaran"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Major adverse cardiovascular events (MACEs) remain a leading cause of poor prognosis following acute myocardial infarction (AMI). Emerging evidence suggests that adipose tissue-derived adipokines may provide additional information on cardiometabolic risk beyond conventional anthropometric measures. This systematic review and meta-analysis aimed to evaluate the association between circulating adipokines, specifically adiponectin and visfatin, and the occurrence of MACE among patients with AMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed\/MEDLINE, Scopus, and Cochrane Library was performed from inception to identify cohort studies reporting adiponectin or visfatin levels in adult AMI patients with and without MACE during follow-up. Pooled mean differences (MD) with 95% confidence intervals (CI) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five cohort studies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009707 AMI patients) conducted across China, Taiwan, Japan, and Poland, with follow-up durations ranging from 2 to 43 months, were included. Adiponectin levels were lower in MACE patients (MD=-2.85 [95% CI -5.42 to -0.27,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200994%), while visfatin levels were significantly higher in the MACE group (MD\u2009=\u20092.99 [95% CI 1.51 to 4.47,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001]; I\n                      <jats:sup>2=<\/jats:sup>\n                      0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lower adiponectin and higher visfatin levels are associated with MACE occurrences in AMI patients, whereas BMI did not demonstrate significant discriminatory value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-06120-0","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:36:16Z","timestamp":1781264176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of adipokines with major adverse cardiovascular events following acute myocardial infarction: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Auda","family":"Nadira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Sunita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bima Diokta","family":"Alparisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Cheryl","family":"Fayza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Syifa","family":"Rahmatika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putri","family":"Karisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nova","family":"Sylviana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mas Rizky A.A","family":"Syamsunarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"6120_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41569-023-00912-z","volume":"20","author":"DJ Pi\u00f1eiro","year":"2023","unstructured":"Pi\u00f1eiro DJ, Codato E, Mwangi J, Eisel\u00e9 J-L, Narula J. Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals. Nat Reviews Cardiol. 2023;20:577\u20138.","journal-title":"Nat Reviews Cardiol"},{"key":"6120_CR2","unstructured":"World Health Organization(WHO). Cardiovascular diseases (CVDs). World Health Organization. 2025. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds).\u00a0Cited 2025 Nov 29."},{"key":"6120_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1186\/s12872-024-04409-6","volume":"24","author":"Z Liu","year":"2024","unstructured":"Liu Z, Cheng J, Zhou S, Li X, Yang M, Zhang Y. Prediction of major adverse cardiovascular events following acute myocardial infarction using electrocardiogram DETERMINE score. BMC Cardiovasc Disord. 2024;24:705.","journal-title":"BMC Cardiovasc Disord"},{"key":"6120_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4274\/balkanmedj.galenos.2022.2022-11-56","volume":"40","author":"F \u015eayl\u0131k","year":"2023","unstructured":"\u015eayl\u0131k F, \u00c7\u0131nar T, Hay\u0131ro\u011flu M\u0130. Effect of the obesity paradox on mortality in patients with acute coronary syndrome: a comprehensive meta-analysis of the literature. Balkan Med J. 2023;40:93.","journal-title":"Balkan Med J"},{"key":"6120_CR5","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3889\/oamjms.2021.7661","volume":"9","author":"V Podzolkov","year":"2021","unstructured":"Podzolkov V, Pokrovskaya A, Bazhanova U, Vargina T, Knyazeva SA, Vanina D. The role of adipokines in cardiovascular pathology. Open Access Macedonian J Med Sci. 2021;9:794\u2013800.","journal-title":"Open Access Macedonian J Med Sci"},{"key":"6120_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.31083\/j.fbl2908286","volume":"29","author":"S Li","year":"2024","unstructured":"Li S, Han X, Song J, Dong M, Xie T. Mechanism of action and risk prediction of adiponectin in cardiovascular diseases. Front Bioscience-Landmark. 2024;29:286.","journal-title":"Front Bioscience-Landmark"},{"key":"6120_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cca.2020.11.010","volume":"512","author":"L Zhou","year":"2021","unstructured":"Zhou L, Li J-Y, He P-P, Yu X-H, Tang C-K. Resistin: Potential biomarker and therapeutic target in atherosclerosis. Clinica chimica acta. 2021;512:84\u201391.","journal-title":"Clinica chimica acta"},{"key":"6120_CR8","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1002\/jcp.30345","volume":"236","author":"A Dakroub","year":"2021","unstructured":"Dakroub A, Nasser SA, Kobeissy F, Yassine HM, Orekhov A, Sharifi-Rad J, et al. Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases. J Cell Physiol. 2021;236:6282\u201396.","journal-title":"J Cell Physiol"},{"key":"6120_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12872-020-01549-3","volume":"20","author":"M Zheng","year":"2020","unstructured":"Zheng M, Lu N, Ren M, Chen H. Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction. BMC Cardiovasc Disord. 2020;20:271.","journal-title":"BMC Cardiovasc Disord"},{"key":"6120_CR10","doi-asserted-by":"publisher","first-page":"E100","DOI":"10.25011\/cim.v38i3.22705","volume":"38","author":"W-C Hung","year":"2015","unstructured":"Hung W-C, Yu T-H, Hsu C-C, Lu L-F, Chung F-M, Tsai I-T, et al. Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction. Clin Invest Med. 2015;38:E100\u20139.","journal-title":"Clin Invest Med"},{"key":"6120_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1253\/circj.71.675","volume":"71","author":"K Shioji","year":"2007","unstructured":"Shioji K, Moriwaki S, Takeuchi Y, Uegaito T, Mutsuo S, Matsuda M. Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ J. 2007;71:675\u201380.","journal-title":"Circ J"},{"key":"6120_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5551\/jat.3533","volume":"17","author":"S-S Huang","year":"2010","unstructured":"Huang S-S, Huang P-H, Chen Y-H, Chiang K-H, Chen J-W, Lin S-J. Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. J Atheroscler Thromb. 2010;17:295\u2013303.","journal-title":"J Atheroscler Thromb"},{"key":"6120_CR13","first-page":"581","volume":"29","author":"K Piestrzeniewicz","year":"2008","unstructured":"Piestrzeniewicz K, Luczak K, Goch JH. Value of blood adipose tissue hormones concentration\u2013adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction. Neuroendocrinol Lett. 2008;29:581\u20138.","journal-title":"Neuroendocrinol Lett"},{"key":"6120_CR14","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"6120_CR15","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"6120_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"6120_CR17","doi-asserted-by":"crossref","unstructured":"Riley RD, Moons KG, Snell KI, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ. 2019;364:k4597.","DOI":"10.1136\/bmj.k4597"},{"key":"6120_CR18","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","volume":"61","author":"JL Peters","year":"2008","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61:991\u20136.","journal-title":"J Clin Epidemiol"},{"key":"6120_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"6120_CR20","doi-asserted-by":"publisher","first-page":"101484","DOI":"10.1016\/j.cegh.2023.101484","volume":"25","author":"M Prasad","year":"2024","unstructured":"Prasad M. Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clin Epidemiol Global Health. 2024;25:101484.","journal-title":"Clin Epidemiol Global Health"},{"key":"6120_CR21","doi-asserted-by":"publisher","first-page":"15627","DOI":"10.3390\/ijms232415627","volume":"23","author":"W Han","year":"2022","unstructured":"Han W, Yang S, Xiao H, Wang M, Ye J, Cao L, et al. Role of adiponectin in cardiovascular diseases related to glucose and lipid metabolism disorders. Int J Mol Sci. 2022;23:15627.","journal-title":"Int J Mol Sci"},{"key":"6120_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4103\/ijpvm.IJPVM_193_20","volume":"11","author":"TMD Nguyen","year":"2020","unstructured":"Nguyen TMD. Adiponectin: role in physiology and pathophysiology. Int J Prev Med. 2020;11:136.","journal-title":"Int J Prev Med"},{"key":"6120_CR23","doi-asserted-by":"publisher","first-page":"1268756","DOI":"10.3389\/fimmu.2023.1268756","volume":"14","author":"E Semerena","year":"2023","unstructured":"Semerena E, Nencioni A, Masternak K. Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker. Front Immunol. 2023;14:1268756.","journal-title":"Front Immunol"},{"key":"6120_CR24","doi-asserted-by":"crossref","unstructured":"Lin Y-T, Chen L-K, Jian D-Y, Hsu T-C, Huang W-C, Kuan T-T, et al. Visfatin Promotes Monocyte Adhesion by Upregulating ICAM-1 and VCAM-1 Expression in Endothelial Cells via Activation of p38-PI3K-Akt Signaling and Subsequent ROS Production and IKK\/NF-\u03baB Activation. Cellular Physiology & Biochemistry (Cell Physiol Biochem Press GmbH & Co KG). 2019;52(6):1398-1411.","DOI":"10.33594\/000000098"},{"key":"6120_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4103\/tcmj.tcmj_317_23","volume":"36","author":"CF Albab","year":"2024","unstructured":"Albab CF, Mahardika NP. The obesity paradox exists in Asia: a systematic review and meta-analysis of body mass index effects on clinical outcomes following percutaneous coronary intervention in Asia. Tzu Chi Med J. 2024;36:387\u201395.","journal-title":"Tzu Chi Med J"},{"key":"6120_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCRESAHA.121.320157","volume":"130","author":"L Gan","year":"2022","unstructured":"Gan L, Liu D, Xie D, Bond Lau W, Liu J, Christopher TA, et al. Ischemic heart-derived small extracellular vesicles impair adipocyte function. Circul Res. 2022;130:48\u201366.","journal-title":"Circul Res"},{"key":"6120_CR27","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.3390\/jcm12237212","volume":"12","author":"G De Napoli","year":"2023","unstructured":"Napoli G, Pergola V, Basile P, De Feo D, Bertrandino F, Baggiano A, et al. Epicardial and pericoronary adipose tissue, coronary inflammation, and acute coronary syndromes. J Clin Med. 2023;12:7212.","journal-title":"J Clin Med"},{"key":"6120_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri2921","volume":"11","author":"N Ouchi","year":"2011","unstructured":"Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85\u201397.","journal-title":"Nat Rev Immunol"},{"key":"6120_CR29","doi-asserted-by":"publisher","first-page":"1077290","DOI":"10.3389\/fcvm.2022.1077290","volume":"9","author":"T Li","year":"2023","unstructured":"Li T, Yan Z, Fan Y, Fan X, Li A, Qi Z, et al. Cardiac repair after myocardial infarction: A two-sided role of inflammation-mediated. Front Cardiovasc Med. 2023;9:1077290.","journal-title":"Front Cardiovasc Med"},{"key":"6120_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00395-021-00852-0","volume":"116","author":"L Pearce","year":"2021","unstructured":"Pearce L, Davidson SM, Yellon DM. Does remote ischaemic conditioning reduce inflammation? A focus on innate immunity and cytokine response. Basic Res Cardiol. 2021;116:12.","journal-title":"Basic Res Cardiol"},{"key":"6120_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrcardio.2016.185","volume":"14","author":"N Ruparelia","year":"2017","unstructured":"Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat reviews Cardiol. 2017;14:133\u201344.","journal-title":"Nat reviews Cardiol"},{"key":"6120_CR32","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.metabol.2014.06.011","volume":"63","author":"JR Kizer","year":"2014","unstructured":"Kizer JR. Adiponectin, cardiovascular disease, and mortality: parsing the dual prognostic implications of a complex adipokine. Metab Clin Exp. 2014;63:1079.","journal-title":"Metab Clin Exp"},{"key":"6120_CR33","doi-asserted-by":"publisher","first-page":"ehaf784","DOI":"10.1093\/eurheartj\/ehaf784.1663","volume":"46","author":"L Liberale","year":"2025","unstructured":"Liberale L, Bruno F, Wang Y, Carbone F, Scuricini A, Ramoni D, et al. Adipocytokines and risk of ischaemic events in acute coronary syndromes: an age-dependent relationship. Eur Heart J. 2025;46:ehaf784.","journal-title":"Eur Heart J"},{"key":"6120_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12944-019-1168-3","volume":"18","author":"L Yang","year":"2019","unstructured":"Yang L, Li B, Zhao Y, Zhang Z. Prognostic value of adiponectin level in patients with coronary artery disease: a systematic review and meta-analysis. Lipids Health Dis. 2019;18:227.","journal-title":"Lipids Health Dis"},{"key":"6120_CR35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.tem.2017.03.004","volume":"28","author":"Y Wang","year":"2017","unstructured":"Wang Y, Ma XL, Lau WB. Cardiovascular adiponectin resistance: the critical role of adiponectin receptor modification. Trends Endocrinol Metabolism. 2017;28:519\u201330.","journal-title":"Trends Endocrinol Metabolism"},{"key":"6120_CR36","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1042\/CS20190578","volume":"133","author":"SR Anthony III","year":"2019","unstructured":"Anthony SR, Guarnieri AR, Gozdiff A, Helsley RN, Phillip Owens A III, Tranter M. Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis. Clin Sci. 2019;133:2329\u201344.","journal-title":"Clin Sci"},{"key":"6120_CR37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s12276-023-00967-5","volume":"55","author":"E Kankuri","year":"2023","unstructured":"Kankuri E, Finckenberg P, Leinonen J, Tarkia M, Bj\u00f6rk S, Purhonen J, et al. Altered acylcarnitine metabolism and inflexible mitochondrial fuel utilization characterize the loss of neonatal myocardial regeneration capacity. Exp Mol Med. 2023;55:806\u201317.","journal-title":"Exp Mol Med"},{"key":"6120_CR38","doi-asserted-by":"publisher","first-page":"1368516","DOI":"10.3389\/fimmu.2024.1368516","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Wang Y, Qi B, Lang Y, Zhang Z, Ma J, et al. IL6\/adiponectin\/HMGB1 feedback loop mediates adipocyte and macrophage crosstalk and M2 polarization after myocardial infarction. Front Immunol. 2024;15:1368516.","journal-title":"Front Immunol"},{"key":"6120_CR39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13578-023-01097-1","volume":"13","author":"S Tang","year":"2023","unstructured":"Tang S, Li R, Ma W, Lian L, Gao J, Cao Y, et al. Cardiac-to-adipose axis in metabolic homeostasis and diseases: special instructions from the heart. Cell Bioscience. 2023;13:161.","journal-title":"Cell Bioscience"},{"key":"6120_CR40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.atherosclerosis.2011.11.038","volume":"220","author":"AL Beatty","year":"2012","unstructured":"Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis. 2012;220:587\u201392.","journal-title":"Atherosclerosis"},{"key":"6120_CR41","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3389\/fendo.2019.00842","volume":"10","author":"Y Liu","year":"2019","unstructured":"Liu Y, Vu V, Sweeney G. Examining the potential of developing and implementing use of adiponectin-targeted therapeutics for metabolic and cardiovascular diseases. Front Endocrinol. 2019;10:842.","journal-title":"Front Endocrinol"},{"key":"6120_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-5-1","volume":"5","author":"AR Da Baker","year":"2006","unstructured":"Baker AR, Da Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006;5:1.","journal-title":"Cardiovasc Diabetol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06120-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06120-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06120-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:22:37Z","timestamp":1787095357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06120-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6120"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06120-0","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"725"}}